Short answer
Enliven Therapeutics, Inc. (ELVN) filed an 8-K current report with the SEC on March 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Enliven Therapeutics (ELVN) reported Q4 and full-year 2025 financial results via press release dated March 3, 2026.
Enliven Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Enliven Therapeutics (ELVN) reported Q4 and full-year 2025 financial results via press release dated March 3, 2026
- Full financial details in Exhibit 99.1: press release contains key figures not reproduced in this filing item
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Enliven Therapeutics, Inc. 8-K filings
Get the next ELVN 8-K as it lands
Follow ELVN for push alerts, or ask the research agent what this filing means.